Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221344 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 3 to 4
    • Eligibility criteria expanded, about 31 words
    • Secondary endpoints: details revised at 6 of 15 entries
  2. Eligibility criteria expanded, about 9 words
    • Study title revised
    v5
  3. Study sites: 1 to 3v4
  4. Eligibility criteria expanded, about 86 wordsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2025 to Nov 18, 2025
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment due to AD and mild AD dementia.
Trial Details
NCT Number NCT07221344
Lead Sponsor Arrowhead Pharmaceuticals
Conditions
(from sponsor)		 Alzheimer Disease, Alzheimer Disease, Early Onset
Related terms Alzheimer Disease
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov